Manifest-2, a global, phase 3, randomized, double-blind, active-control study of CPI 0610 and ruxolitinib vs. placebo and ruxolitinib in JAKI-treatment-naive myelofibrosis patients

被引：0

作者：

Mead, Adam ^{[1
]}

Mascarenhas, John ^{[2
]}

Gerds, Aaron ^{[3
]}

Luptakova, Katarina ^{[4
]}

Christo, Jessica ^{[4
]}

Wang, Jing ^{[4
]}

Colak, Gozde ^{[4
]}

Shao, James ^{[4
]}

Bobba, Suresh ^{[4
]}

Trojer, Patrick ^{[4
]}

Humphrey, Jeffrey ^{[4
]}

Verstovsek, Srdan ^{[5
]}

Harrison, Claire ^{[6
]}

机构：

[1] Univ Oxford, Oxford, England

[2] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA

[3] Cleveland Clin, London, Cleveland, England

[4] Constellat Pharmaceut, Cambridge, England

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[6] Guys & St Thomas Hosp, London, England

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2021年 / 193卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BSH2021-PO

引用

页码：101 / 102

页数：2

共 50 条

[1] MANIFEST-2, a global, phase 3, randomized, double-blind, active-control study of CPI-0610 and Ruxolitinib vs. placebo and Ruxolitinib in JAKi-treatment-naive Myelofibrosis (MF) patients
Al-Ali, H. K.
Mascarenhas, J.
Harrison, C.
Luptakova, K.
Wang, J.
Colak, G.
Shao, J.
Bobba, S.
Trojer, P.
Humphrey, J.
Verstovsek, S.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 164 - 164
[2] MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI-0610 and Ruxolitinib vs Placebo and Ruxolitinib in JAKi Treatment-Naive Myelofibrosis Patients
Mascarenhas, John
Harrison, Claire
Luptakova, Katarina
Wang, Jing
Colak, Gozde
Shao, James
Bobba, Suresh
Trojer, Patrick
Humphrey, Jeffrey
Verstovsek, Srdan
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S363 - S363
[3] MANIFEST-2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL STUDY OF CPI 0610 AND RUXOLITINIB VS. PLACEBO AND RUXOLITINIB IN JAK INHIBITOR-TREATMENT-NAIVE MYELOFIBROSIS PATIENTS
Passamonti, F.
Palandri, F.
Mascarenhas, J.
Harrison, C.
Patriarca, A.
Vannucchi, A.
Luptakova, K.
Wang, J.
Colak, G.
Shao, J.
Bobba, S.
Trojer, P.
Humphrey, J.
Verstovsek, S.
HAEMATOLOGICA, 2021, 106 (10) : 81 - 82
[4] MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI-0610 and Ruxolitinib Vs. Placebo and Ruxolitinib in JAK-Inhibitor-Naive Myelofibrosis Patients
Mascarenhas, John
Harrison, Claire
Luptakova, Katarina
Christo, Jessica
Wang, Jing
Mertz, Jennifer A.
Colak, Gozde
Shao, James
Bobba, Suresh
Trojer, Patrick
Senderowicz, Adrian
Humphrey, Jeffrey S.
Verstovsek, Srdan
BLOOD, 2020, 136
[5] Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naive Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study
Rampal, Raajit K.
Grosicki, Sebastian
Chraniuk, Dominik
Abruzzese, Elisabetta
Bose, Prithviraj
Gerds, Aaron T.
Vannucchi, Alessandro M.
Palandri, Francesca
Lee, Sung-Eun
Gupta, Vikas
Lucchesi, Alessandro
Oh, Stephen T.
Kuykendall, Andrew T.
Patriarca, Andrea
Alvarez-Larran, Alberto
Mesa, Ruben
Kiladjian, Jean-Jacques
Talpaz, Moshe
Harris, Morgan
Kays, Sarah-Katharina
Jegg, Anna-Maria
Li, Qing
Brown, Barbara
Harrison, Claire N.
Mascarenhas, John
BLOOD, 2023, 142
[6] Phase III MANIFEST-2: pelabresib plus ruxolitinib vs placebo plus ruxolitinib in JAK inhibitor treatment-naive myelofibrosis
Harrison, Claire N.
Gupta, Vikas K.
Gerds, Aaron T.
Rampal, Raajit
Verstovsek, Srdan
Talpaz, Moshe
Kiladjian, Jean-Jacques
Mesa, Ruben
Kuykendall, Andrew T.
Vannucchi, Alessandro M.
Palandri, Francesca
Grosicki, Sebastian
Devos, Timothy
Jourdan, Eric
Wondergem, Marielle J.
Al-Ali, Haifa Kathrin
Buxhofer-Ausch, Veronika
Alvarez-Larran, Alberto
Patriarca, Andrea
Kremyanskaya, Marina
Mead, Adam J.
Akhani, Sanjay
Sheikine, Yuri
Colak, Gozde
Mascarenhas, John
FUTURE ONCOLOGY, 2022, 18 (27) : 2987 - 2997
[7] Preliminary Report of MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), in Combination with Ruxolitinib, in JAK Inhibitor (JAKi) Treatment Naive Myelofibrosis Patients
Harrison, Claire N.
Patriarca, Andrea
Mascarenhas, John
Kremyanskaya, Marina
Hoffman, Ronald
Schiller, Gary J.
Leber, Brian
Devos, Timothy
Kabir, Sujan
Senderowicz, Adrian
Mertz, Jennifer
Trojer, Patrick
Shao, James
Gupta, Vikas
BLOOD, 2019, 134
[8] A randomized, double-blind, placebo-controlled phase 3 study of parsaclisib plus ruxolitinib in patients with myelofibrosis who have suboptimal response to ruxolitinib
Yacoub, Abdulraheem
Stouffs, Michael
Zhou, Feng
Assad, Albert
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 112 - 113
[9] ReTHINK: A randomized, double-blind, placebo controlled, multicenter, phase 3 study of ruxolitinib in early myelofibrosis patients.
Passamonti, Francesco
Kiladjian, Jean-Jacques
Vannucchi, Alessandro M.
Reiter, Andreas
Bharathy, Savita
Iommazzo, Dana
Stalbovskaya, Viktoriya
Gopalakrishna, Prashanth
Mesa, Ruben A.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[10] Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in JAKi-naive myelofibrosis.
Mascarenhas, John
Maher, Keri Renee
Rampal, Raajit
Bose, Prithviraj
Podoltsev, Nikolai Alexandrovich
Hong, Junshik
Wang, Xulong
Kye, Steve
Harrison, Claire
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →